Smart Patients Get Smart Care™

The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients

Loading Events

« All Events

  • This event has passed.

Toronto CLL Support Group

September 13, 2021 @ 7:00 pm - 9:00 pm

|Recurring Event (See all)

An event every 2 months that begins at 7:00 pm on day Second of the month, repeating until November 14, 2022

Toronto CLL Support Group

Take a break and read all about it

CLL Society Ed Forum On Demand: CLL Society and Huntsman 5th Annual Patient & Caregiver Educational Forum

In partnership with Huntsman Cancer Institute (HCI), CLL Society invites you to attend our virtual Ed Forum focused on chronic lymphocytic leukemia (CLL). Featured speakers will present the basics of CLL diagnosis, early management, clinical trials, treatment options, COVID-19 considerations for CLL patients, patient perspectives, and strategies to become an effective self-advocate.

CLL Society Organizes Joint Effort Urging Government Agencies to Focus on Continued COVID-19 for the Immunocompromised

In light of the FDA’s announcements regarding the discontinuation of Emergency Use Authorization for both Evusheld  and Bebtelovimab, CLL Society and eight other patient advocacy organizations sent a letter to federal officials requesting them to immediately undertake thirteen specific actions that would help protect the estimated seven million Americans who are immunocompromised against COVID-19.

FDA Announces Evusheld is Not Currently Authorized for Emergency Use in the U.S.

As of 1/26/23, Evusheld (tixagevimab co-packaged with cilgavimab) is no longer available as Pre-Exposure Prophylaxis (PrEP) in the United States. That decision was made because as the virus continued to mutate, now over 90% of SARS-CoV-2 variants of concerns (VOC) circulating in the U.S. are no longer believed to be neutralized by the monoclonal antibody (mAb) cocktail.

Paid Research Opportunity

A major pharmaceutical manufacturer has commissioned market research to understand the unique issues and concerns of those diagnosed CLL.

Your participation in this project will help to expand on new treatments, as well as enhance awareness and improve education about Blood Cancers.

ASH 2022: Dr. Clare Sun Explains Her Research on Sudden Death Among a Small Number of Chronic Lymphocytic Leukemia (CLL) Patients Using Ibrutinib

Dr. Sun was interviewed by Dr. Brian Koffman, a physician, CLL patient, and executive vice president and chief medical officer of CLL Society, at the ASH 2022 meeting in New Orleans. In the interview, she elaborates on the research results and recommendations on how patients can avoid cardiac issues while taking ibrutinib or other Bruton’s tyrosine kinase (BTK) inhibitors.

ASH 2022: Dr. John Seymour on the Adverse Event Burden of Acalabrutinib vs. Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)

In this interview, our own Dr. Brian Koffman interviewed Dr. John Seymour, Director of the Department of Hematology at Peter MacCallum Cancer Centre & Royal Melbourne Hospital in Melbourne, Australia. They discussed the latest updates to the safety data from the ELEVATE R/R study, which was the first clinical trial to compare acalabrutinib and ibrutinib head-to-head.

CLL Society’s COVID-19 Update for the Week of January 23, 2023

Please read this week’s update which is pertinent to all of those who are immunocompromised, including anyone living with CLL/SLL regardless of treatment status. The goal of these weekly COVID-19 updates is to keep our community informed of the latest information available throughout the upcoming months as we approach what Dr. Brian Koffman has referred to as the potential “winter of discontent.”

Do You Want To Boost Your Business?

drop us a line and keep in touch


September 13, 2021
7:00 pm - 9:00 pm


Toronto CLL Society Support Group
105 Wellness Way
Toronto, Ontario M3N 0B1 Canada
+ Google Map